Aurobindo Pharma's Subsidiary Secures License Deal for Leukemia Drug, Stock Surges by 2%

23 Jun 2023 , 02:29 PM

Aurobindo Pharma’s share price experienced a 2.5 % increase on June 23 as one of its subsidiaries entered into a sub-licensing agreement with the Medicines Patent Pool for Nilotinib Capsules.

Aurobindo Pharma’s wholly owned subsidiary, Eugia Pharma Specialities Limited (Eugia), has signed a voluntary sub-licensing agreement with the Medicines Patent Pool (MPP). The agreement aims to develop and market Nilotinib capsules, originally developed by Novartis, for the treatment of chronic myeloid leukemia in 44 low and middle-income countries.

This includes seven countries where patents for the drug are either pending or already in force. The production of the product will take place at Eugia Pharma’s facility located in Medchal, Malkajgiri district, Telangana.

The voluntary license granted by the MPP allows Eugia to develop, manufacture, and distribute generic Nilotinib Capsules in select markets.

K Nithyananda Reddy, Vice Chairman & Managing Director of Aurobindo Pharma, expressed excitement about the sublicense agreement and highlighted that it is the first of its kind signed by the MPP for a cancer treatment in low and middle-income countries.

The addition of Nilotinib Capsules to Aurobindo’s oncology portfolio is expected to strengthen the company’s position in the generic oncology space. Aurobindo Pharma is eager to start supplying the product at the earliest to help reduce the risk of chronic myeloid leukemia (CML) in certain patients.

For feedback and suggestions, write to us at [e-mail]